Literature DB >> 16916399

National breast cancer audit: overview of invasive breast cancer management.

Astrid V Cuncins-Hearn1, Margaret Boult, Wendy Babidge, Helen Zorbas, Elmer Villanueva, Alison Evans, David Oliver, James Kollias, Tom Reeve, Guy Maddern.   

Abstract

BACKGROUND: The National Breast Cancer Audit is an initiative of the Breast Section of the Royal Australasian College of Surgeons collecting surgical information in early breast cancer. It is managed in conjunction with the Australian Safety and Efficacy Register of New Interventional Procedures - Surgical. An overview of results for invasive breast cancer from January 1999 until December 2004 is presented to provide preliminary data for participating surgeons.
METHODS: Invasive breast cancer cases were retrieved from the National Breast Cancer Audit database for the 274 participating breast surgeons in Australia and New Zealand. Data for a variety of clinical parameters were analysed to provide an overview of the diagnostic, histological, surgical and adjuvant therapy management issues.
RESULTS: There were 25,026 cases of invasive breast cancer. Annual percentages of mammographically detected cancers from 1999 to 2004 did not differ significantly. Breast-conserving surgery rates also remained stable at 60%. Margins were involved in 5% of patients; an additional 9% had final margins of less than 1 mm. Radiotherapy followed breast-conserving surgery in most cases (86%). Patients undergoing mastectomy with large tumours (>5 cm) underwent radiotherapy in 71% of cases. When at least four lymph nodes were positive, radiotherapy followed mastectomy in the majority (75%) of cases. The most frequently carried out axillary procedure was a level 2 dissection. Chemotherapy was received by 78% of oestrogen receptor negative, axillary node positive, postmenopausal patients. Tamoxifen was used in the majority (83%) of oestrogen receptor positive cases.
CONCLUSION: Surgeons contributing their invasive breast cancer data show a high quality of treatment. Some further improvement may be possibly related to excision margins and tamoxifen prescription for oestrogen receptor negative cancers. Chemotherapy prescription might also warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916399     DOI: 10.1111/j.1445-2197.2006.03846.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

1.  Early data from the first population-wide breast cancer-specific registry in Hong Kong.

Authors:  Polly Cheung; W K Hung; Catherine Cheung; Amy Chan; T T Wong; Lawrence Li; Sharon W W Chan; K W Chan; Peter Choi; W H Kwan; C C Yau; Emily Y Y Chan; Stephen C K Law; Daisy Kwan
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

2.  Women's Acceptance of Overdetection in Breast Cancer Screening: Can We Assess Harm-Benefit Tradeoffs?

Authors:  Anne Stiggelbout; Tessa Copp; Gemma Jacklyn; Jesse Jansen; Gerrit-Jan Liefers; Kirsten McCaffery; Jolyn Hersch
Journal:  Med Decis Making       Date:  2019-11-13       Impact factor: 2.583

3.  Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China.

Authors:  Yun Wu; Yiqun Han; Pei Yu; Quchang Ouyang; Min Yan; Xiaojia Wang; Xichun Hu; Zefei Jiang; Tao Huang; Zhongsheng Tong; Shusen Wang; Yongmei Yin; Hui Li; Runxiang Yang; Huawei Yang; Yuee Teng; Tao Sun; Li Cai; Hongyuan Li; Xi Chen; Jianjun He; Xinlan Liu; Shune Yang; Youlin Qiao; Jinhu Fan; Jiayu Wang; Binghe Xu
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

4.  A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.

Authors:  Can Zhou; Jian jun He; Jing Li; Jin hu Fan; Bin Zhang; Hong jian Yang; Xiao ming Xie; Zhong hua Tang; Hui Li; Jia yuan Li; Shu lian Wang; You lin Qiao; Rong Huang; Pin Zhang
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

5.  The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.

Authors:  Yiqun Han; Yun Wu; Hangcheng Xu; Jiayu Wang; Binghe Xu
Journal:  Int J Clin Oncol       Date:  2022-01-18       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.